Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcell Lederer

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Nucleic Acids Research|August 8, 2020
The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancerSimon Müller, Nadine Bley, Bianca Busch, et al.
Nucleic Acids Research|October 30, 2018
IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent mannerSimon Müller, Markus Glaß, Anurag K Singh, et al.
NAR Cancer|July 28, 2021
Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in miceSimon Müller, Alice Wedler, Janina Breuer, et al.
RNA Biology|September 3, 2020
IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancerNadine Bley, Annekatrin Schott, Simon Müller, et al.
Nucleic Acids Research|February 1, 2024
RAVER1 hinders lethal EMT and modulates miR/RISC activity by the control of alternative splicingAlice Wedler, Nadine Bley, Markus Glaß, et al.
NAR Cancer|February 26, 2025
The IGF2BP1 oncogene is a druggable m<sup>6</sup>A-dependent enhancer of YAP1-driven gene expression in ovarian cancerAnnekatrin Schott, Theresa Simon, Simon Müller, et al.
Signal Transduction and Targeted Therapy|December 24, 2025
Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancerNadine Bley, Alexander Rausch, Simon Müller, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Nucleic Acids Research|August 8, 2020
The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancerSimon Müller, Nadine Bley, Bianca Busch, et al.
Nucleic Acids Research|October 30, 2018
IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent mannerSimon Müller, Markus Glaß, Anurag K Singh, et al.
NAR Cancer|July 28, 2021
Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in miceSimon Müller, Alice Wedler, Janina Breuer, et al.
RNA Biology|September 3, 2020
IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancerNadine Bley, Annekatrin Schott, Simon Müller, et al.
Nucleic Acids Research|February 1, 2024
RAVER1 hinders lethal EMT and modulates miR/RISC activity by the control of alternative splicingAlice Wedler, Nadine Bley, Markus Glaß, et al.
NAR Cancer|February 26, 2025
The IGF2BP1 oncogene is a druggable m<sup>6</sup>A-dependent enhancer of YAP1-driven gene expression in ovarian cancerAnnekatrin Schott, Theresa Simon, Simon Müller, et al.
Signal Transduction and Targeted Therapy|December 24, 2025
Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancerNadine Bley, Alexander Rausch, Simon Müller, et al.
Pageof 3